ArticleJournal of medical case reports2025
Kaposi sarcoma in a female patient with multiple sclerosis: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKaposi sarcoma is a vascular neoplasm linked to human herpes virus 8 and presents in four main variants. The development of Kaposi sarcoma, particularly the iatrogenic form, in younger women with autoimmune conditions such as multiple sclerosis is exceedingly rare and presents unique diagnostic and therapeutic challenges. CASE PRESENTATION: We report the case of a 48-year-old Arab woman with an 18-year history of multiple sclerosis managed with corticosteroids, who developed cutaneous iatrogenic Kaposi sarcoma on her lower extremities. The diagnosis was delayed for 2 years as the lesions were initially misattributed to her underlying multiple sclerosis. A skin biopsy eventually confirmed Kaposi sarcoma, and staging revealed localized cutaneous disease with no visceral involvement. The patient was treated with weekly paclitaxel, showing a favorable response. Due to conflict-related logistical issues, treatment was temporarily switched to vincristine and vinorelbine, which resulted in disease progression and adverse effects. Paclitaxel was successfully reintroduced, leading to sustained clinical improvement, and 2 years after completing therapy, the patient remains in good health with no evidence of Kaposi sarcoma recurrence or multiple sclerosis exacerbation.
conclusionThis case expands the known clinical and demographic spectrum of Kaposi sarcoma, underscoring the importance of maintaining a high index of suspicion in atypical patient populations to prevent diagnostic delays. The co-occurrence of multiple sclerosis and Kaposi sarcoma underscores the importance of recognizing iatrogenic Kaposi sarcoma in patients receiving immunosuppressive therapy and calls for further research into the complex intersection of autoimmune disorders and iatrogenic treatment-related immune dysregulation in oncogenesis. This report underscores the importance of individualized, persistent therapeutic strategies in managing Kaposi sarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.